Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price objective upped by investment analysts at BMO Capital Markets from $80.00 to $84.00 in a report issued on Thursday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 29.61% from the stock’s current price.

Other analysts also recently issued reports about the company. Stifel Nicolaus assumed coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They set a “buy” rating and a $104.00 target price for the company. Canaccord Genuity cut their target price on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $82.00 target price on shares of Sage Therapeutics in a research report on Tuesday, June 13th. BidaskClub downgraded Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 28th. Finally, HC Wainwright upped their target price on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.25.

Sage Therapeutics (NASDAQ SAGE) traded down 7.90% on Thursday, reaching $64.81. The company’s stock had a trading volume of 1,833,702 shares. The company’s market cap is $2.43 billion. The company has a 50-day moving average price of $81.85 and a 200 day moving average price of $74.87. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the previous year, the company posted ($1.08) earnings per share. On average, equities research analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/sage-therapeutics-inc-sage-pt-raised-to-84-00.html.

Several institutional investors have recently bought and sold shares of the company. State of Wisconsin Investment Board acquired a new position in Sage Therapeutics in the 2nd quarter worth about $1,991,000. Schwab Charles Investment Management Inc. increased its holdings in Sage Therapeutics by 1.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after purchasing an additional 1,593 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in Sage Therapeutics in the 2nd quarter worth about $202,000. Spark Investment Management LLC acquired a new position in Sage Therapeutics in the 1st quarter worth about $4,086,000. Finally, Amalgamated Bank acquired a new position in Sage Therapeutics in the 1st quarter worth about $262,000.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.